Breaking News
Sort by:
Top Post
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
EVERSANA® Announces Partnership with ChemoMouthpiece, LLC to Support U.S. Launch & Commercialization of Medical Device to Help Cancer Patients Manage and Treat Oral Mucositis
EVERSANA, a leading provider of commercialization services to the life science industry, today announced a […]
Xspray Pharma Partners with EVERSANA for the Treatment of Chronic Myeloid Leukemia (CML) and Acute Lymphatic Leukemia (ALL)
Xspray Pharma AB has signed an agreement with EVERSANA to support the U.S. launch and commercialization of […]
EVERSANA Unveils Global Price and Market Access Solution NAVLIN by EVERSANA
EVERSANA™, the pioneer of next generation commercial services to the global life sciences industry, today […]
EVERSANA Acquires Protean; Strengthens Operational Strategy and Excellence in Market Access, Channel and Patient Services
EVERSANA™, the pioneer of next-generation commercial services to the global life sciences industry, today announced […]
EVERSANA ™ Expands Medical Information and Integrated Compliance Services Across Europe
EVERSANA ™, the pioneer of next generation commercial services to the global life sciences industry, today […]
GENinCode Announces Major US Commercialisation Partnership with EVERSANA
GENinCode UK Limited, the cardiovascular disease company focused on predictive genetics for the prevention of […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more